Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform

Positive

AI Analysis

Summary

Brii Biosciences unveiled BRiSC, a proprietary siRNA discovery platform for developing next-generation dual-targeting siRNA medicines. The initial focus is on prevalent metabolic dysfunctions with overlapping comorbidities.

Outcome Details

Unveiling of proprietary BRiSC platform for discovery of dual-targeting siRNA therapeutics, initially focused on metabolic dysfunctions

Importance:4/10

Sentiment:

0.30

siRNARNAiplatformmetabolic diseasedual-targetingdrug discoverypreclinical

Related Companies

$GBIO

Read the original article

Published by PR Newswire Pharma on October 15, 2026 11:30 AM

Read Original